A phase I trial with the TLR9 agonist (GNKG168) supports the immunomodulatory capacity of a TLR9 agonists in vivo, showing that in children with acute leukemia and present minimal residual disease a unique immune activation pattern can be induced (Ronsley et al., 2019). Here, TLR9 is linked to acute leukemia.